The HemOnc Pulse

The HemOnc Pulse

By Rahul Banerjee, MDScience
Download on the App Store

The HemOnc Pulse episodes

  • Putting AI to Work in Blood Cancer Clinical Trials

    The HemOnc Pulse host, Rahul Banerjee, MD, of Fred Hutchinson Cancer Center, returns for Part 2 of a conversation on the evolving role of AI in hematologic oncology. He is joined by Louis Williams, MD, of Cleveland Clinic, to discuss AI applications in blood cancer research, including clinical trial matching and design, data analysis, safety oversight, and streamlining clinical trial operations.

    19 min
  • The Transformative Potential of AI in Hematologic Malignancies

    How is AI transforming hematologic cancer care? In this episode of The HemOnc Pulse, Rahul Banerjee, MD, of the Fred Hutchinson Cancer Institute, interviews Louis Williams of Cleveland Clinic on this topic. Together, the experts explore AI scribes, machine learning, genomic data, early detection, and how AI could reshape treatment decisions and patient monitoring.

    14 min
  • Rewriting the Treatment Playbook for MDS/MPN and Myelofibrosis

    In this Editor’s Special episode of The HemOnc Pulse, MD Anderson Cancer Center’s Naval Daver, MD, and Naveen Pemmaraju, MD, discuss MDS/MPN overlap conditions and research examining combination therapy with ruxolitinib and azacitidine (AZA), including its potential to improve disease response, symptom control, and outcomes.

    22 min
  • Community-Based CAR-T Therapy: Expanding Access, Navigating Challenges

    In this episode of HemOnc Pulse, host Dr. Rahul Banerjee of Fred Hutchinson Cancer Center sits down with Dr. Gary Simmons, a hematologist-oncologist at Virginia Oncology Associates, to explore the evolving role of community-based cellular therapy programs and the future of patient access to innovative treatments.

    12 min
  • MRD at the Regulatory Crossroads in Multiple Myeloma

    In this Editor’s Special Episode of The HemOncPulse, a conversation with Nicholas Richardson, DO, MPH, vice president of clinical development at Precision for Medicine, focuses on the evolving regulatory role of measurable residual disease in multiple myeloma clinical trials. The discussion is designed to contextualize recent FDA draft guidance for a broad clinical and research audience.

    15 min
  • The Data Problem in T-Cell Lymphoma Care

    In this episode of TheHemOnc Pulse, Rahul Banerjee, MD, speaks with Francine Foss, MD, professor of medicine and dermatology at Yale School of Medicine, about the evolving landscape of T-cell lymphomas. Dr Foss discusses the unique challenges of studying and treating rare diseases such as cutaneous T-cell lymphoma and explains why real-world data are essential to closing evidence gaps. The conversation highlights the role of collaborative registries in tracking treatment patterns, outcomes, and access to care across community and academic settings. Dr Foss also shares how both clinicians and patients can participate in these efforts to strengthen research, inform future clinical trials, and improve outcomes for patients with T-cell lymphomas.

    9 min
  • XPO1 Inhibition Across the Myeloma Journey

    This Editor’s Special Episode of The HemOnc Pulse features Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discussing treatment strategies for relapsed/refractory multiple myeloma and where selinexor-based regimens fit in today’s evolving landscape. Drawing from real-world cases, Dr. Richardson explores care for patients before CAR T, after CAR T relapse, and in between—highlighting how selinexor can be used flexibly across multiple lines, including as a bridge to future immunotherapies. The conversation emphasizes individualized, dynamic treatment planning to balance disease control, tolerability, and long-term goals in an increasingly complex era of myeloma care.

    18 min

About The HemOnc Pulse

From the publisher's feed

Blood Cancers Today and the Society of Hematologic Oncology bring you The HemOnc Pulse, a podcast hosted by Rahul Banerjee, MD, covering all topics in the world of hematologic oncology.